Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated at Wall Street Zen

Wall Street Zen began coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report sent to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada restated a “sector perform” rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Barclays cut their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, May 14th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Finally, Truist Financial cut their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4.50.

Sangamo Therapeutics Price Performance

SGMO opened at $0.49 on Thursday. The company has a market capitalization of $115.30 million, a price-to-earnings ratio of -0.66 and a beta of 1.46. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The business has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $1.28.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The firm had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. Equities analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SGMO. Golden State Equity Partners increased its holdings in shares of Sangamo Therapeutics by 2,592.3% in the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 313,587 shares in the last quarter. Sageworth Trust Co bought a new position in shares of Sangamo Therapeutics in the fourth quarter valued at $61,000. SBI Securities Co. Ltd. bought a new position in shares of Sangamo Therapeutics in the fourth quarter valued at $28,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company’s stock valued at $1,162,000 after buying an additional 35,926 shares in the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics in the fourth quarter valued at $25,000. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.